Age Related Macular Degeneration Clinical Trial
Official title:
A Randomized Controlled Trial to Assess if Attending an Interactive, Self-management Group, 'Living With Vision Loss', in Addition to Having Vision Rehabilitation in Our Clinic, Improves Patients' Quality of Life
Verified date | February 2017 |
Source | Massachusetts Eye and Ear Infirmary |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
120 Patients with visual acuity <6/12 will be randomized to receive either usual care or participate in a 6-week, 2 hour 'Living with Vision Loss' program led by trained leaders. We hypothesize that a structured self-management low-vision rehabilitation program provides a greater improvement in participation in daily activities, and improves quality of life in vision-impaired people compared to the provision of the usual low vision rehabilitation services. We also plan to document barriers that prevent patients with low vision (visual acuity <6/12) from participating in self-management course.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 2016 |
Est. primary completion date | December 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 55 Years to 95 Years |
Eligibility |
Inclusion Criteria: - Clients who have attended the MEEI Vision Rehabilitation for the first time within 12 months - Visual acuity of <6/12 in the better eye with habitual correction - Age 55+ years - Living independently (not in a nursing home) - English speaking - No cognitive impairment - Adequate hearing to respond to normal conversation Exclusion Criteria: - vestibular disease |
Country | Name | City | State |
---|---|---|---|
United States | Vision Rehabilitation Center | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Massachusetts Eye and Ear Infirmary |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Impact of Vision Impairment Questionnaire (IVI) | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03963817 -
Snapshot Camera for AMD
|
||
Recruiting |
NCT04929756 -
Eye Movement Rehabilitation in Low Vision Patients
|
||
Completed |
NCT04779398 -
Association of MPOD Values With Blue Light.
|
||
Terminated |
NCT03275753 -
Visual Function Tests in Age-related Macular Degeneration
|
||
Recruiting |
NCT03609307 -
Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial
|
Phase 2/Phase 3 | |
Completed |
NCT02909985 -
Visual Activity Evoked by Infrared in Humans After Dark Adaptation
|
N/A | |
Completed |
NCT02556723 -
Intravitreal Injections of Ziv-aflibercept for Macular Diseases
|
N/A | |
Active, not recruiting |
NCT01943396 -
Treatment of AMD With Rheohemapheresis /RHF/
|
Phase 4 | |
Completed |
NCT00963339 -
Age-Related Macular Degeneration (AMD) - Usability Study
|
N/A | |
Completed |
NCT00376701 -
Combination Therapy for Age-Related Macular Degeneration.
|
Phase 2 | |
Terminated |
NCT00347165 -
Intravitreal Bevacizumab for Age-Related Macular Degeneration
|
Phase 2 | |
Completed |
NCT00800995 -
Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD)
|
Phase 3 | |
Completed |
NCT04689789 -
OCTA and Retinal Angiomatous Proliferation
|
||
Completed |
NCT02567604 -
Development of Core Outcomes for Age-related Macular Degeneration (AMD) Interventions- Caregivers' Perspective
|
||
Completed |
NCT02173496 -
Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)
|
||
Recruiting |
NCT01991730 -
Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients
|
N/A | |
Active, not recruiting |
NCT01657669 -
Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results
|
Phase 4 | |
Completed |
NCT00776763 -
Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab
|
Phase 2 | |
Completed |
NCT00791570 -
Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy
|
Phase 1 | |
Completed |
NCT00413829 -
Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)
|
Phase 2 |